300318 Beijing Bohui Innovation Biotechnology Group
- 5.08
- -0.05-0.97%
Beijing Bohui Innovation Biotechnology Group News
Bohui Innovation (300318.SZ): Currently, the in vitro diagnosis business is mainly HPV testing products and trace element testing products
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by specific subjects on May 14, 2024, on “Other than HPV and human trace elements, what is the sales status of other IVD products and spectrometers?” The company replied that the company's in vitro diagnostic business is currently mainly HPV testing products and trace element testing products.
Bohui Innovation (300318.SZ): Currently, sales of blood products account for a relatively high proportion of retail sales
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by a specific target on May 14, 2024, on “What is the ratio of the company's blood products sales side, hospital side, and retail side? What is the ratio of dealers' sales to their own sales? What is the sales channel situation?” The company replied that the company's current sales of blood products account for a relatively high proportion of sales on the retail side, and the hospital side also has a certain percentage, and the sales method is mainly distribution. At present, the company's sales channels have covered major provinces across the country.
Bohui Innovation (300318.SZ): Currently, the yield rate of albumin and static acrylic remains at the average level of the industry
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by specific subjects on May 14, 2024, on “The company's yield rate of albumin and hydroxypropyl?” The company replied that at present, the yield rate of albumin and hydroxypropyl remains at the average level of the industry.
Bohui Innovation (300318.SZ): The new process of static acrylic is undergoing amplification test research
Gelonghui, May 11 | Bohui Innovation (300318.SZ) said on the investor interactive platform that the company's new Jingbing process is undergoing scale-up testing and research, and that human coagulation factor VIII is preparing a production registration declaration.
Bohui Innovation (300318.SZ): No synthetic biotechnology-related business
Gelonghui, May 11 | Bohui Innovation (300318.SZ) said on the investor interactive platform that the company is currently not engaged in synthetic biological related business.
Bohui Innovation (300318.SZ): The increase in performance in the first quarter was mainly due to the increase in revenue and gross profit of the blood products business
Gelonghui, May 10 | Bohui Innovation (300318.SZ) said on the investor interactive platform that the company's first quarter performance growth was mainly due to the increase in revenue and gross profit of the blood products business. The company will continue to focus on its main business, implement established strategies, pay close attention to scientific management, and continuously improve profit levels.
Bohui Innovation (300318.SZ) announced first-quarter results, net profit of 19.86 million yuan, an increase of 283.90% over the previous year
Bohui Innovation (300318.SZ) released its report for the first quarter of 2024, achieving 2 operating income during the reporting period...
Bohui Innovation (300318.SZ): Currently, the main business covers in vitro diagnosis, biological products, etc.
Gelonghui, April 3 | Bohui Innovation (300318.SZ) said on the investor interactive platform that the company's main business currently covers in vitro diagnosis, biological products, etc., and belongs to the medical technology field. The company and its major subsidiaries are also national high-tech enterprises. After searching for public information, it was determined that the selection of sailing enterprises was organized by the State Council's State-owned Assets Administration Commission, an initiative of the State Council's State-owned Assets Administration Commission to cultivate innovative state-owned enterprises.
Bohui Innovation (300318.SZ): Plans to invest 3.3 billion yuan to build the “Bohui Biotech Shijiazhuang Modern Biopharmaceutical Industry Base” project
On March 26, Ge Longhui Innovation (300318.SZ) announced that the company and its subsidiary Bohui Biopharmaceutical (Shijiazhuang) Co., Ltd. signed the “Bohui Biotech Shijiazhuang Modern Biopharmaceutical Industry Base Project Cooperation Framework Agreement” with the Shijiazhuang Municipal People's Government and the Shijiazhuang High-tech Industrial Development Zone Management Committee. The company and its subsidiary Shijiazhuang Bohui plan to invest 3.3 billion yuan in instalments to build the “Bohui Biotech Shijiazhuang Modern Biopharmaceutical Industry Base” project in the Shijiazhuang High-tech Zone. The project will mainly build the company's biopharmaceutical business operation and management headquarters, R&D center, and 1,500 tons of intelligence
Bohui Innovation (300318.SZ) Langfang Bohui has now completed the renovation of facilities and equipment
Gelonghui, Feb. 5 | Bohui Innovation (300318.SZ) said on the investor interactive platform, 1. Currently, the Yunnan Blood Products Project is undergoing relocation procedures in accordance with the “Regulations on the Administration of Blood Products” and other regulations. 2. Langfang Bohui has now completed the renovation of facilities and equipment, and the supplementary registration application for changes in the product production process has also been accepted by the State Drug Administration. After the relevant inspections are passed, official production will commence.
Bohui Innovation (300318.SZ): Expected net loss of 15.12 million yuan to 30.23 million yuan in 2023
On January 30, Gelonghui Innovation (300318.SZ) announced that it expects a net loss of RMB 15.12 million to RMB 30.23 million in 2023, after deducting non-net loss of RMB 18.36 million to RMB 33.47 million. The revenue scale and gross profit level of the company's blood products business both increased significantly year over year. Products such as human blood albumin and intravenous human immunoglobulin have benefited from the continuous increase in market demand. Product prices and sales have increased year-on-year, and the scale of revenue has increased dramatically. At the same time, the company adheres to the concept of lean management. The production and management level of subsidiary blood products companies continues to improve, the amount of pulp collection continues to increase, and the product cost is the same ratio
Bohui Innovation (300318.SZ): No separate test strip for mycoplasma pneumoniae
On December 4, Glonghui Innovation (300318.SZ) stated on the investor interactive platform that the company does not have a separate test sheet for mycoplasma pneumoniae, but there are 2 types of test products containing mycoplasma pneumoniae: 1. The respiratory pathogen six-fold nucleic acid detection kit (PCR-fluorescent probe method) is currently in the registration stage. 2. Multiple nucleic acid detection kits for respiratory pathogens (biochip method) have now been studied and marketed, and can be used in fields such as Centers for Disease Control and Prevention.
Bohui Innovation (300318.SZ) passed the high-tech enterprise certification
On November 30, Glonghui Innovation (300318.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Beijing Municipal Science and Technology Commission, the Beijing Municipal Finance Bureau, and the Beijing Municipal Taxation Bureau of the State Administration of Taxation, and the Beijing Municipal Taxation Bureau. The company once again successfully passed the high-tech enterprise certification.
Bohui Innovation (300318.SZ): Luoping Plasma Station, a subsidiary of the holding subsidiary, obtained a single plasma collection license
Gelonghui November 22|Bohui Innovation (300318.SZ) announced that recently, Luoping Bohui Single Plasma Collection Co., Ltd. (“Luoping Plasma Station”), a subsidiary of Bohui Biopharmaceuticals (Hebei) Co., Ltd., a holding subsidiary of Beijing Bohui Innovation Biotechnology Group Co., Ltd., obtained the “Single Plasma Collection License” issued by the Yunnan Provincial Health Commission. Luoping Plasma Station was approved for registration and allowed to practice.
Bohui Innovation (300318.SZ) released the first three quarter results, net profit of 14.1372 million yuan, an increase of 135.96%
Bohui Innovation (300318.SZ) released its report for the third quarter of 2023, achieving an operating income of 8.0 in the first three quarters...
Bohui Innovation (300318.SZ): It is actively coordinating with all relevant departments to promote the relocation of production qualifications for the Yunnan Blood Processing Project. The official date of operation cannot be accurately predicted
Glonghui, Oct. 20 丨 Some investors asked Bohui Innovation (300318.SZ) on the investor interactive platform, “What step is the migration of visas and qualifications between the Hebei Bohui base and the Yunnan Bohui base? Have Hebei Bohui and Yunnan Bohui reached the trial operation stage?” The company replied that the transfer of production qualifications is a relocation from another location and requires inspection by the government drug administration department and its approval before it can be completed. Currently, the company is actively coordinating with all relevant departments to promote the relocation of production qualifications for the Yunnan Blood Processing Project. The official date of operation cannot be accurately predicted.
Bohui Innovation (300318.SZ): There are no diet medicine projects under development
Glonghui, Oct. 20 | An investor asked Bohui Innovation (300318.SZ) on the investor interactive platform, “Does your company develop diet pills?” The company replied that the company has no diet drug development projects.
Bohui Innovation (300318.SZ): The amount of pulp collected in the first half of 2023 is about 202 tons, and it is expected that the annual pulping volume in 2023 will exceed 400 tons
Glonghui, September 21丨Bohui Innovation (300318.SZ) investor relations activity record table shows that the number of pulping stations currently in operation by the company is 15. The pulping volume in the first half of 2023 is about 202 tons, and it is expected that the pulping volume for the whole year of 2023 will exceed 400 tons. The Yunnan Blood Processing Project has completed engineering construction and equipment installation, and is in the process of relocating production qualifications. The relocation of production qualifications is an offsite relocation. It requires acceptance, inspection, and approval by the government drug administration department before it can be completed. Currently, the company is actively coordinating with all relevant departments to promote the relocation of production qualifications for the Yunnan Blood Processing Project.
Bohui Innovation (300318.SZ): Some of the pulp stations in operation are in operation, and the slurry collection volume of new pulping stations is still climbing in recent years
In response to research from institutional investors, GLONGHUI INNOVATION (300318.SZ) recently stated in response to research from institutional investors that some of the pulp stations operated by the company are new pulping stations in recent years, and the amount of pulping is still climbing. On the other hand, the slurry extraction volume of a certain pulping station has a lot to do with its geographical location, regional population, pulp donation habits, etc., and cannot be generalized.
Bohui Innovation (300318.SZ): The company's pulp extraction volume will continue to grow
In response to research from institutional investors, GLONGHUI INNOVATION (300318.SZ) recently said in response to research from institutional investors that in recent years, the company's pulp stations have been increasing every year. Currently, there are 15 pulp stations in operation, 6 are still under construction or awaiting inspection in Yunnan, 2 are under construction in Inner Mongolia; moreover, the pulping volume of new pulp stations usually has a climbing period of about 3 years. Overall, the company's pulp extraction volume will continue to grow.
Analysis
Price Target
No Data
